CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,024,322 | -11.2% | 37,221 | +9.4% | 0.00% | 0.0% |
| Q2 2023 | $1,153,891 | -28.9% | 34,008 | -24.6% | 0.00% | 0.0% |
| Q1 2023 | $1,623,706 | +0.3% | 45,128 | +24.2% | 0.00% | 0.0% |
| Q4 2022 | $1,618,916 | +71.9% | 36,323 | +8.4% | 0.00% | 0.0% |
| Q3 2022 | $942,000 | -79.5% | 33,512 | -80.3% | 0.00% | -66.7% |
| Q2 2022 | $4,589,000 | +80.0% | 170,214 | +127.4% | 0.00% | +200.0% |
| Q1 2022 | $2,550,000 | -32.6% | 74,857 | -23.5% | 0.00% | -50.0% |
| Q4 2021 | $3,782,000 | +54.7% | 97,896 | +116.3% | 0.00% | +100.0% |
| Q3 2021 | $2,444,000 | +111.1% | 45,259 | +30.7% | 0.00% | 0.0% |
| Q2 2021 | $1,158,000 | +2216.0% | 34,631 | +1338.2% | 0.00% | – |
| Q1 2021 | $50,000 | -96.5% | 2,408 | -97.1% | 0.00% | -100.0% |
| Q4 2020 | $1,441,000 | -75.4% | 82,232 | -79.1% | 0.00% | -75.0% |
| Q3 2020 | $5,847,000 | – | 394,273 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 1,017,524 | $20,961,000 | 7.56% |
| Octagon Capital Advisors LP | 561,398 | $11,565,000 | 4.36% |
| COMMODORE CAPITAL LP | 369,951 | $7,621,000 | 3.04% |
| Opaleye Management Inc. | 985,000 | $20,291,000 | 2.98% |
| VR Adviser, LLC | 1,240,610 | $25,557,000 | 2.77% |
| TSP Capital Management Group, LLC | 359,229 | $7,400,000 | 2.61% |
| RTW INVESTMENTS, LP | 3,908,947 | $80,524,000 | 1.26% |
| Ghost Tree Capital, LLC | 250,000 | $5,150,000 | 1.21% |
| Tri Locum Partners LP | 196,672 | $4,051,000 | 1.00% |
| Redmile Group, LLC | 3,387,788 | $69,788,000 | 0.98% |